Group-24

The Company

NuMat Medtech develops stable and disruptive bioactive surfaces based on cost-effective and easy to obtain natural molecules for medical implants, to provide a solution capable of regenerating bone tissue, enabling osseointegration, introducing anti-inflammatory and antiresorptive properties and reducing the risk of infection.

Market Challenges and Value Proposition

Group 27Created with Sketch.

Pressure on price

NuMat's Coatings are expected to be price competitive.
Cost effective and available raw materials.
Simple, robust and scalable technologies based on wet chemistry.

Group 26Created with Sketch.

Adverse outcomes

NuMat's Coatings may decrease implant failure risk.
Anti-inflammatory and antibacterial properties, should enhance hard and soft tissue integration (decreasing infections and promoting osteointegration).

Group 28Created with Sketch.

Innovation need

NuMat technologies are patented solutions
based on natural molecules.

Improved properties compared to the current market
solutions. Compatible with most implant materials.

Group 25Created with Sketch.

Unattended niche market

NuMat develops coatings for unmet needs.
Patients with impaired bone quality (i.e. diabetic,osteoporotic) due to osteoinductive properties that stimulate bone formation locally.

Group-24

Product Focus: Bioactive surfaces

Bioactive surfaces made of natural molecules covalently bound to titanium or alloys will be a combination of an established medical device with proven clinical success with a first-in-class and game changing coating that provides multifunctional activity.

Recurso 1@3x Copy
Group-24

Target Market

The area of biomedical implants is a sector with a growing potential demand due to the progressive aging of the population and the repercussion in the improvement of the quality of life of implant patients, being the main markets United States and Europe.